Abstract:Hypoxia or low oxygen concentration in tumor microenvironment has widespread effects ranging from altered angiogenesis and lymphangiogenesis, tumor metabolism, growth, and therapeutic resistance in different cancer types. A large number of these effects are mediated by the transcription factor hypoxia inducible factor 1⍺ (HIF-1⍺) which is activated by hypoxia. HIF1⍺ induces glycolytic genes and reduces mitochondrial respiration rate in hypoxic tumoral regions through modulation of various cells in tumor microenvironment like cancer-associated fibroblasts. Immune evasion driven by HIF-1⍺ further contributes to enhanced survival of cancer cells. By altering drug target expression, metabolic regulation, and oxygen consumption, hypoxia leads to enhanced growth and survival of cancer cells. Tumor cells in hypoxic conditions thus attain aggressive phenotypes and become resistant to chemo- and radio- therapies resulting in higher mortality. While a number of new therapeutic strategies have succeeded in targeting hypoxia, a significant improvement of these needs a more detailed understanding of the various effects and molecular mechanisms regulated by hypoxia and its effects on modulation of the tumor vasculature. This review focuses on the chief hypoxia-driven molecular mechanisms and their impact on therapeutic resistance in tumors that drive an aggressive phenotype. Impact statement Hypoxia contributes to tumor aggressiveness and promotes growth of many solid tumors that are often resistant to conventional therapies. In order to achieve successful therapeutic strategies targeting different cancer types, it is necessary to understand the molecular mechanisms and signaling pathways that are induced by hypoxia. Aberrant tumor vasculature and alterations in cellular metabolism and drug resistance due to hypoxia further confound this problem. This review focuses on the implications of hypoxia in an inflammatory TME and its impact on the signaling and metabolic pathways regulating growth and progression of cancer, along with changes in lymphangiogenic and angiogenic mechanisms. Finally, the overarching role of hypoxia in mediating therapeutic resistance in cancers is discussed.

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions

Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions

Tumor hypoxia: From basic knowledge to therapeutic implications

Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

Hypoxia: Intriguing Feature in Cancer Cell Biology

Role of hypoxia in the tumor microenvironment and targeted therapy

Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies

Hypoxia signaling: Challenges and opportunities for cancer therapy

Hypoxic tumor microenvironment: Implications for cancer therapy

Role of hypoxia in cancer therapy by regulating the tumor microenvironment

The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies

Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways

Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications

Tumor hypoxia and heterogeneity: Challenges and opportunities for the future

The role of hypoxic microenvironment in the progress of tumor

Hypoxia-activated nanomedicines for effective cancer therapy

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation

Therapeutic targeting of the hypoxic tumour microenvironment

Hypoxia-regulated gene network in drug resistance and cancer progression